



Pressrelease
1 February 2006

The last patient has been enrolled to the alphaHGA study in Thailand

Tripep today confirmed that the 48th and last patient has been included in the alphaHGA study in Thailand. This means that all patients will have concluded the study by the last week of March, 2006.

The main purpose of the study is to evaluate the tolerability and safety at different dose levels, but as the patients included are HIV positive, possible impact on the HIV infection will also be evaluated. All virology samples from the patients have been collected and are kept frozen. These will be analysed when the last patient has concluded the treatment. The preliminary results are expected to be available before the Annual General Meeting on 5 April, 2006.

Furthermore, Tripep announces that more than 99 % of the warrants TO1, series F, has been subscribed to as of 31 January, 2006, which contributes SEK 10m to the company.

For more information, please contact:

Rolf L. Nordström, Chairman, Tripep AB
Tel: +44 20 7495 1480, mobile phone: +44 7776 137 400
E-mail: rolf.l.nordstrom@btinternet.com

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se

Tripep AB is a Swedish biotechnology research company that develops and commercialises candidate drugs based on patented and proprietary technologies. Its main focuses are:

- research and clinical development of alphaHGA, an HIV-inhibiting drug,*
- research and clinical development of ChronVac-C[®], a therapeutic vaccine against hepatitis C.*
- preclinical research focusing on the development of the therapeutic and prophylactic vaccines against influenza A and HIV*
- the RAS[®] technology platform*

For more details of the company's technologies, please refer to the company's web site at www.tripep.se